What is Ivermectin? -- Efficacy and results
Nobel Prize Kitasato Institute An antiparasitic infectious disease drug developed by Dr. Satoshi Omura, a special honorary professor at Kitasato University.
It has been taken by about 300 million people annually for the past 30 years or more. It has saved more than a billion people from blindness as a treatment for parasitic infections.
Dr. Satoshi Omura discovered a new species of actinomycete in the soil of a golf course in Shizuoka Prefecture. He developed ivermectin through joint research with Merck & Co., Inc. of the United States.
It is provided free of charge by Merck & Co. and the Kitasato Institute to the World Health Organization (WHO) and is used by more than 300 million people annually in Africa. To date, more than a billion people have been saved from two tropical diseases, and the disease is projected to be eradicated in the 2020s. It is highly effective against parasites such as nematodes, mites and maggots, and as an anthelmintic for animals, it has greatly contributed to the development of the world livestock industry.
Currently, it is made as a generic drug all over the world, and the overseas selling price is around 100 yen.
Dr. Satoshi Omura received the Nobel Prize in Physiology or Medicine in 2015 for his discovery of new treatments for infectious diseases caused by nematode infestation.
Researchers at the World Health Organization (WHO) highly valued ivermectin as "compared to any tropical disease drug that has been released so far, and have an excellent effect on the order of magnitude," and cooperated with Merck & Co. and Kitasato University. In 1987, it began to be distributed free of charge to residents of tropical regions such as Africa and Central and South America. Above all, the simple way of taking tablets once a year with water has raised the WHO's reputation.
Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations by Nature.com
The future: new potential/new target diseases
Ivermectin is already deployed to treat a variety of infections and diseases, most of which primarily afflict the world’s poor. But it is the new opportunities with respect to ivermectin usage, or re-purposing it to control a completely new range of diseases, that is generating interest and excitement in the scientific and global health research communities.
* Myiasis
* Trichinosis
* Disease vector control
* Malaria
* Leishmaniasis
* American trypanosomiasis (Chagas disease)
* Schistosomiasis
* Rosacea
* Epilepsy
* Neurological disease
* Asthma
* Antiviral (e.g. HIV, dengue, encephalitis)
* Antibacterial (tuberculosis and Buruli ulcer)
* Anti-cancer
Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2
In conclusion, both ivermectin and remdesivir could be considered potential drugs for the treatment of COVID-19. Ivermectin efficiently binds to the viral S protein as well as the human cell surface receptors ACE-2 and TMPRSS2; therefore, it might be involved in inhibiting the entry of the virus into the host cell. It also binds to Mpro and PLpro of SARS-CoV-2; therefore, it might play a role in preventing the post-translational processing of viral polyproteins. The highly efficient binding of ivermectin to the viral N phosphoprotein and nsp14 is suggestive of its role in inhibiting viral replication and assembly.
Interview of Dr. Satoshi Omura
Agriculture is a scientific activity-Farmers are scientists-
Novel prize speech by Dr. Satoshi Omura
awarded for a discovery; • of major importance in Life Science or medicine & that has changed the scientific paradigm and which confers the "greatest benefit on mankind"
https://www.nobelprize.org/uploads/2018/06/omura-lecture-slides.pdf
The Huffington Post
Mectizan (Ivermectin) on Merck Website
In Japan, it is approved and prescribed as the following therapeutic agents.
1. Scabies = ticks
2. Intestinal fecal nematode disease
Characteristics of ivermectin
1. Excellent balance as a pharmaceutical product in terms of safety, availability, and manufacturing cost
2. It has been used for many years since its development for more than 40 years.
3. Only mild and rare side effects have been observed in 3 billion doses worldwide
<Side effects>
Very rare. No worries about serious side effects, according to statistical data prescribed as a scabies drug
・ Diarrhea (especially those with weak gastrointestinal tract) Due to parasite die-off
= Temporary symptoms such as itching and headaches occur because the parasites expel the toxins that have accumulated inside when they die.
·itch, nausea, dizzy
<Effectiveness of Ivermectin for COVID-19>
1) Analysis of all significant studies concerning the use of ivermectin for COVID-19
As of 3 Sep, 2021
2) Effects announced by FLCCC (Front Line COVID-19 Critical Care), an association of doctors engaged in the treatment of COVID-19
In March 2008, FLCCC (Front Line COVID-19 Critical Care), led by Professor Paul E. Marik, chief of respiratory and critical care patients at Eastern Virginia Medical School in Virginia, USA. Alliance) was established. FLCCC was one of the first to evaluate reports of clinical trials of ivermectin that are widespread worldwide, incorporated ivermectin into its protocol, and began to aggregate and evaluate clinical trials of other groups.
The result was on October 31, 2020, with the title "Ivermectin has the potential to be a global solution to the Covid-19 pandemic," and as a result of scrutinizing about 30 papers, it was directed to the world. Was sent.
1) Studies since 2012 have shown that ivermectin inhibits the replication of many viruses, including influenza, Zika, and dengue.
2) Ivermectin inhibits SARS-CoV-2 virus replication and binding to infected human body tissues.
3) Ivermectin has strong anti-inflammatory properties, indicating that it significantly inhibits both cytokine production and transcription, where inflammation is most pronounced.
4) Ivermectin significantly reduces viral load and protects against organ damage when infected with SARS-CoV-2 or similar coronavirus.
5) Ivermectin prevents the transmission and development of COVID-19 infection in people who come into contact with the infected person.
6) Ivermectin accelerates recovery and is administered early in symptoms to prevent exacerbations in patients with mild to moderate illness.
7) Ivermectin accelerates recovery and avoidance of inpatients entering the ICU and dying.
8) Ivermectin reduces the mortality rate of critically ill patients with COVID-19.
9) Ivermectin causes a significant reduction in mortality in widely used areas.
10) The safety, availability, and cost of ivermectin are near zero drug interactions, in addition to only the mild and rare side effects observed with nearly 40 years of use and billions of doses. Given that, it's almost unmatched.
11) The World Health Organization has long included ivermectin in its "essential medicine list".
Original Article
The Uttar Pradesh government said early use of ivermectin helped maintain low positive rates and keep deaths low.
Is this why ivermectin was so relentlessly banned? Pfizer's coronary drug in clinical trials has "almost the same mechanism of action as ivermectin.
Pfizer Launches Final Study For COVID Drug That's Suspiciously Similar To 'Horse Paste'
On September 27, Pfizer Inc. announced the start of a Phase 2/3 trial of a COVID prophylaxis designed to prevent the onset of disease in people who may have come into contact with people infected with coronas.
Coincidentally, the Pfizer drug shares at least one mechanism of action with ivermectin. Ivermectin is an antiparasitic drug that has been used in humans for decades and has also been shown to function as a protease inhibitor against Covid-19 for its antiviral effects.
Pfizer's new drug, jokingly called "Pfizermectin," is described by Pfizer as a "potent protease inhibitor.
In a March 2021 article, "Investigation of the binding effects of ivermectin on key proteins of SARS-CoV-2 pathogenesis,"
＞ Ivermectin was found to be a blocker of proteases and human TMPRSS2.
According to the website, Pfizer's new drug called "PF-07321332
＞ PF-07321332 is an investigational SARS-CoV-2-3 CL protease inhibitor antiviral therapy.
This is truly a matter of human and animal health.
This is exactly what ivermectin, a prophylactic drug used for many reasons in both humans and animals, has done. But unlike this experimental drug from Pfizer, ivermectin may have already saved hundreds of thousands of lives in reality, from India to Brazil.
The announcement of Pfizer's new drug trial comes amidst a campaign in the U.S. and around the world to smear people who use ivermectin as a "horse anthelmintic.
Institut Pasteur Preclinical Study: Ivermectin a Powerful Immunomodulatory Drug Targeting SARS-CoV-2
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
As it says here, "FDA-approved drugs," it appears that the U.S. Food and Drug Administration had "approved" ivermectin for the treatment of corona as recently as last June.
The highlights of the summary of this paper say the following
Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2).
Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) and can produce a reduction of approximately 1/5000th of the virus in 48 hours in cell culture.
Ivermectin is FDA-approved for parasitic infections, so it could be used to treat coronas.
Ivermectin is widely available because it is included in the WHO model list of essential medicines.
この記事が気に入ったらサポートをしてみませんか？